18 research outputs found
PIN28 Comparative Effectiveness of Triple Therapy Versus Dual Therapy for Chronic Hepatitis C Virus Infection in Kazakhstan
No full textCurrently, 23 thousand people (registered) are suffering from Hepatitis C in Germany (more 60% genotype 1). TThe licensing of direct-acting antivirals heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. Clinical studies showed a significant increase in sustained virological response rates from 38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly introduced triple therapy with Telaprevir (TVR+PR) compared to dual therapy (PR) for the treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated patients
PIN23 Economic Evaluation of Protease Inhibitors for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Kazakhstan
No full text
Comparative Cost-Effectiveness Analysis Of Catheter Directed Thrombolisys With Urokinase And Alteplase For Treatment Of Acute Peripheral Artery Disease
No full text
The Adjusting use of Cost-Effectiveness Analysis in Formulary Management Within The Kazakhstan Healthcare System
No full textClinical effectiveness and cost-effectiveness of renal denervation for resistant hypertension
No full textComparative Effectiveness of Triple Therapy Versus Dual Therapy for Chronic Hepatitis C Virus Infection in Kazakhstan
No full textPCV81 Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective
No full textApixaban, dabigatran, and rivaroxaban are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Kazakhstan.The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhsta
